: Supported for both adult and pediatric patients.
For full prescribing information and format items, clinicians can reference the FDA Center for Drug Evaluation and Research records. 125545
Approved under BLA , this biosimilar offers flexible dosing schedules for various patient needs: Adult CKD : 50 to 100 units/kg 3 times weekly. Pediatric CKD : 50 units/kg 3 times weekly. : Supported for both adult and pediatric patients
Increased competition in the biologics space continues to drive down healthcare costs while maintaining high standards for patient safety. 125545